Navigation Links
Patient Safety Technologies Reports Second Quarter 2012 Results
Date:8/10/2012

y, including but not limited to including the impact from Forward Order revenue, or stocking order revenue (see the Company's Quarterly Report on Form 10-Q for a discussion on the Forward Order).

Non-GAAP measures are provided to enhance investors' overall understanding of the Company's current financial performance, prospects for the future and as a means to evaluate period-to-period comparisons. The Company believes that the use of non-GAAP revenue and operating income provides meaningful supplemental information regarding financial performance by excluding certain expenses and benefits that may not be indicative of recurring core business operating results. The Company believes these non-GAAP measures, which excludes the effects of the Forward Order and the non-cash expenses of depreciation, amortization and stock based compensation (and occasionally along with certain events believed to be one time in nature) when viewed with GAAP results and the accompanying reconciliation, enhances the comparability of results against prior periods and allows for greater transparency of financial results.  The Company believes these non-GAAP measures facilitate management's internal comparison of the Company's financial performance to that of prior periods as well as trend analysis for budgeting and planning purposes. The presentation of these non-GAAP measures is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

About Patient Safety Technologies, Inc. and SurgiCount Medical
Patient Safety Technologies, Inc., through its wholly-owned operating subsidiary SurgiCount Medical, Inc., provides the Safety-Sponge® System, a solution proven to improve patient safety and reduce healthcare costs by preventing one of the most common errors in surgery, retained foreign objects.  For more information, contact SurgiCount Medical, Inc. at (94
'/>"/>

SOURCE Patient Safety Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Watching, Reading and Listening: A New Way to Interact with Patient Information
4. Phreesia identifies over 26% of patients who require additional autism evaluation
5. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
8. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
9. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
10. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
11. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... N.Y. , Nov. 21, 2014  Cardinal Health, ... world,s largest health care services companies, and Henry Schein, ... provider of health care products and services to office-based ... the companies have entered into a long-term strategic agreement ... product offerings to office-based medical practices.  This strategic agreement ...
(Date:11/21/2014)... N.J. , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Krakauer , Chief Executive Officer, will be presenting at the ... New York Palace Hotel in New York ... 2014 at 2:00 PM ET. In addition, Mr. Krakauer and ... available for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... Nov. 20, 2014  The acceptance of two ... AAGL Global Congress demonstrates continued interest in the ... provide bowel control. One of the abstracts, presented by ... Division Chief of Urogynecology and Reconstructive Pelvic Surgery ... Award for Best Written Abstract on Urogynecology/Pelvic Floor ...
Breaking Medicine Technology:Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3
... British Columbia--(BUSINESS WIRE)--Apr 3, 2007 - ... Company(TM),announced today the publication of new ... showing that Allon's product,candidate AL-108 significantly ... the hyperphosphorylation of tau protein in ...
... BASEL, Switzerland, April 3, 2007 (PRIME NEWSWIRE) ... microbiological and,pharmacokinetic profiles of Basilea's (SWX:BSLN) two ... for ceftobiprole, the first anti-MRSA broad-spectrum,cephalosporin in ... for the treatment of invasive fungal infections,yielded ...
Cached Medicine Technology:Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference 2Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 2Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 4Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 5Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 6Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 7
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 The Sports ... Roy Baroff to its team of conflict resolution ... soccer player, coach, and referee. He has over 30 years ... and beyond. , “I'm very excited to connect with SCI ... sports related interests to a program with a complete sports ...
(Date:11/22/2014)... 2014 Wright & Schulte LLC reports ... have been scheduled between October 2016 and April ... Illinois. U.S. District Judge Matthew F. Kennelly, who is ... Order (CMO) on November 6, 2014 that outlined the ... submit documents and other activities in preparation for the ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... using small impulses of electricity. This innovative device is ... // (TENS) technology, which has long been used by ... pain. ,The device comes in the form of a ... in the air from the snoring sound. ,Sensors ...
... scientists have developed a test that can detect the Hepatitis ... by Arieh Yaari of Soroka University Medical Centre // ... people without kidney functions whose blood must be passed through ... SciDev Net. ,Such patients have a high incidence of ...
... British Cardiac Society, the British Hypertension Society, Diabetes ... // and the Stroke Association have collaboratively ... attacks, stroke and hardening of leg arteries. The ... of developing heart attacks by properly maintaining one’s ...
... cannot be cured by taking medications reports a study ... review of eight // clinical trials that complementary and ... occur after alcohol consumption. Some of the common hangover ... diarrhea, dizziness, fatigue, depressed, poor memory. ,Though, ...
... Health experts in the United States fear that if the deadly ... risk since they are vulnerable // to the H5N1 virus. ... 70 lives in Asia and has appeared in parts of Europe ... slaughtered in an effort to contain the virus. However, experts fear ...
... study conducted at Oregon Health & Science University and ... that a perfect molecular mixture present in male-emitted pheromone ... and increased aggression) dictates the sexual behavior of other ... interest. ,The researchers argue that release of ...
Cached Medicine News:Health News:The Chemistry Of Sexual Attraction Between Male And Female Elephants 2
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
Medicine Products: